NCT05184517View on ClinicalTrials.gov

A Feasibility Study to Evaluate the Tolerability of Oph1 Compared to Restasis in Healthy Volunteers

EARLY_PHASE1CompletedINTERVENTIONAL
Enrollment

20

Participants

Timeline

Start Date

January 23, 2023

Primary Completion Date

July 6, 2023

Study Completion Date

September 5, 2023

Conditions
Dry Eye Syndromes
Interventions
DRUG

Oph1

0.5% CsA ophthalmic formulation, twice daily for 4 days and once on the fifth day, one eye (right).

DRUG

Restasis

0.05% CsA ophthalmic formulation twice daily for 4 days and once on the fifth day, one eye (right).

Trial Locations (1)

9103102

Shaare Zedek Medical Center, Jerusalem

All Listed Sponsors
lead

OphRx Ltd.

INDUSTRY